Months after the 'Crypto Black Friday' crash, allegations of platform instability and market manipulation continue to dog Binance, sparking fierce debate about trust and power in the digital asset space.
Despite a bruising year, XRP's legal clarity, banking ambitions, and technical upgrades position it as a speculative recovery play for investors eyeing the next market cycle.
Lean hog futures slipped lower on Friday, contrasting with a steady rise in the CME Lean Hog Index, as traders weighed softer cash prices against stronger wholesale pork values.
While several stocks have posted impressive gains recently, not all momentum stories are built to last. We analyze one company with durable advantages and two where recent rallies may warrant skepticism.
While small-cap stocks can offer overlooked opportunities, their high-risk nature demands careful scrutiny. We examine three companies where valuation and business concerns suggest caution may be warranted.
Saks Global is closing the majority of its Saks OFF 5TH discount locations, including the final two in Massachusetts, amid a corporate restructuring following its recent bankruptcy filing.
In uncertain markets, low-volatility stocks offer comfort but may cap upside potential. We analyze one steady performer and two stocks where stability may signal stagnation, helping investors balance risk and reward.
Amidst a market rally driven by a handful of tech giants, certain volatile stocks present outsized risks. We examine three names where valuation concerns and sector headwinds warrant a cautious approach.
As the digital asset market matures, two powerful forces—comprehensive U.S. regulation and a pivot toward tokenized stable assets—are poised to redefine the trading landscape by 2026, potentially attracting a new wave of capital while curbing volatility.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility, aiming to scale up production of its blockbuster weight-loss therapies like retatrutide amid soaring global demand.
Analyses from multiple artificial intelligence models project divergent paths for Ethereum, Solana, and XRP by 2026, highlighting varying risk-reward profiles based on technological adoption, regulatory landscapes, and market structure.
Israel announces a limited reopening of the Rafah border crossing between Gaza and Egypt this Sunday, permitting the movement of people under strict security protocols for the first time since its capture in May 2024.
Moody's Corporation bolsters its risk analytics arsenal with strategic acquisitions of Numerated Growth Technologies and CAPE Analytics, positioning itself at the center of a private credit market under the regulatory microscope.
With its share price up nearly 40% in a month, Bannerman Energy (ASX:BMN) is drawing intense investor scrutiny ahead of its December quarter report and investor webinar. Analysts weigh whether the uranium developer's rally has outpaced fundamentals.
Ethereum's dominant liquid staking protocol, Lido, has launched its modular stVaults on mainnet, enabling protocols and institutions to create tailored staking solutions. Consensys's Linea and analytics firm Nansen were among the first to deploy, signaling a shift towards more flexible staking infrastructure.
Sugar futures tumbled further this week, with New York prices hitting a 2.5-month low and London white sugar sinking to a five-year trough, as analysts warn of swelling global surpluses driven by record harvests in Brazil and India.
Amid a broader leadership restructuring, financial giant Charles Schwab has appointed its CIO, Dennis Howard, to lead a consolidated unit overseeing technology, operations, and data, signaling a strategic shift to deepen the integration of IT with core business functions.
Despite a trimmed price target from B. Riley, WhiteFiber Inc. (WYFI) secures a pivotal 10-year colocation agreement expected to generate $865 million, spotlighting its role in the expanding AI infrastructure sector.
Shares of restaurant operator Bloomin' Brands have tumbled over 35% in six months, raising questions about its financial health and growth trajectory as analysts flag significant risks.
Haemonetics (NYSE:HAE) sees its price target raised by Barrington Research following its acquisition of Vivasure Medical, with analysts highlighting the deal's potential to bolster its medical device portfolio and drive growth.
